ReviewInternational journal of nanomedicine2026
Application and Future Perspectives of Extracellular Vesicle-Loaded Scaffold in Spinal Cord Injury.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the initial trauma of spinal cord injury (SCI), the secondary injury phase-characterized by inflammation, oxidative stress, neuronal death, and axonal demyelination-establishes an adverse microenvironment that hinders functional recovery. Despite the availability of existing clinical therapies, they often yield suboptimal functional recovery. In this review, the applications and future prospects of extracellular vesicle (EV)-loaded scaffolds for SCI repair are summarized. This review discusses the biological properties and therapeutic action of EVs, as well as limitations of using them as a single agent, such as rapid clearance and poor targeting. Other scaffold loading strategies and types that change in response to the microenvironment are also reviewed. This review highlights the advancement of EV-loaded scaffolds in alleviating secondary injury, controlling inflammation, enhancing neural regeneration and remyelination, and promoting angiogenesis. Microvesicles, a high-capacity and large subtype of EVs with rapid release and functional surface proteins, in particular, have been shown to have multi-target repair capabilities in various disease models. Their integration with scaffolds for SCI is suggested as a promising translational direction. Current challenges encompass subtype standardization, safety evaluation, as well as large-scale production. The review concludes that EV-loaded scaffolds are not just delivery systems, but a regenerative platform that enables spatiotemporal structure-signal synergy. Subtype-specific selection, pathology-stage-directed release, and industry-compliant quality control should be the focus in future studies to develop this strategy beyond basic research into clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.